Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verve Therapeutics Inc (NQ: VERV )

4.600 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verve Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Cathie Wood-Led Ark Invest Buys $9.9M Worth Of Amazon Shares, Also Picks Up Reddit Stock
Via Benzinga
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Leadership Update
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics to Participate in Upcoming Investor Conferences
From Verve Therapeutics
Via GlobeNewswire
After a Serious Setback, Is Verve Therapeutics a Buy?
There are a few silver linings at play here. 
Via The Motley Fool
Cathie Wood's Ark Innovation ETF Sees Sharp Decline Among Top Holdings — Here Are 10-Largest Losers Within ARKF
Cathie Wood's flagship ARK Innovation ETF has been navigating through significant losses, showcasing the challenges faced by some of its major holdings. 
Via Benzinga
Topics ETFs
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024
Discover three biotech stocks handpicked by Cathie Wood, offering groundbreaking therapies and substantial growth potential. 
Via InvestorPlace
3 Underappreciated Stocks That Could 10x in 10 Years
10x stocks are the holy grail of capital investing. So, here are three companies that have the potential to cross that line. 
Via InvestorPlace
VERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q1 2024
VERV stock results show that Verve Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Cathie Wood's Ark Invest Sheds $6.4M Worth Of Coinbase Shares Despite Positive Market Movements, Analyst Upgrade
On Thursday, Cathie Wood-led Ark Invest made a significant move by selling shares of Coinbase Global Inc (NASDAQ:COIN), despite the stock’s positive market performance on the same day. The COIN Trade 
Via Benzinga
Cathie Wood's Ark Invest Buys More Shares Of This Meta Platforms Competitor
Via Benzinga
Nasdaq Down Over 1%; VivoPower International Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dipping over 1% on Tuesday. The Dow traded down 1.07% to 39,142.53 while the NASDAQ fell 1.14% to 16,209.12. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Stumbles, Heads For Worst Day Since February
Stocks are starting the second quarter off on the wrong foot, as profit taking grips Wall Street. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with... 
Via Benzinga
Crude Oil Surges Over 1%; US Factory Orders Increase In February
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday. The Dow traded down 1.05% to 39,152.47 while the NASDAQ fell 1.17% to 16,205.37. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects
The company is now pausing enrollment in the study of its lead asset, VERVE-101. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Verve Therapeutics Announces Updates on its PCSK9 Program
From Verve Therapeutics
Via GlobeNewswire
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
3 Stocks That Could Be the Next Big Thing in Gene Editing
Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks. 
Via InvestorPlace
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Both companies are working on treatments for genetic disorders. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.